Evidence map›Paper›PMID 33608039›Full record

ArticleAlzheimer's research & therapy2021

Introduction of an assessment toolkit associated with increased rate of DLB diagnosis.

A Surendranathan, J Kane, A Bentley, S Barker, R McNally, C Bamford, J-P Taylor, A Thomas, I McKeith, D Burn and 1 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

A SurendranathanDepartment of Psychiatry, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 189, Cambridge, CB2 0QQ, UK. as2489@medschl.cam.ac.uk.
J KaneCentre for Public Health, Queen's University Belfast, Belfast, UK.
A BentleyDepartment of Psychiatry, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 189, Cambridge, CB2 0QQ, UK.
S BarkerInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
R McNallyInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
C BamfordPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
J-P TaylorInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
A ThomasInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
I McKeithInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
D BurnInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
J T O'BrienDepartment of Psychiatry, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 189, Cambridge, CB2 0QQ, UK.
Newcastle University · GBUniversity of Cambridge · GBQueen's University Belfast · GB

Funding

Department of Health DTC-RP-PG-0311-12001
6 · The paper itself

Abstract

backgroundDementia with Lewy bodies (DLB) and dementia in Parkinson's disease (PDD) are recognised to be under-recognised in clinical practice in the UK, with only one third to a half of expected cases diagnosed. We aimed to assess whether clinical diagnostic rates could be increased by the introduction of a structured assessment toolkit for clinicians.

methodsWe established baseline diagnostic rates for DLB and PDD in four memory clinics and three movement disorder/Parkinson's disease (PD) clinics in two separate geographical regions in the UK. An assessment toolkit specifically developed to assist with the recognition and diagnosis of DLB and PDD was then introduced to the same clinical teams and diagnostic rates for DLB and PDD were reassessed. For assessing DLB diagnosis, a total of 3820 case notes were reviewed before the introduction of the toolkit, and 2061 case notes reviewed after its introduction. For PDD diagnosis, a total of 1797 case notes were reviewed before the introduction of the toolkit and 3405 case notes after it. Mean values and proportions were analysed using Student's t test for independent samples and χ

resultsDLB was diagnosed in 4.6% of dementia cases prior to the introduction of the toolkit, and 6.2% of dementia cases afterwards, an absolute rise of 1.6%, equal to a 35% increase in the number of DLB cases diagnosed when using the toolkit (χ

conclusionIntroduction of the assessment toolkit was associated with a significant increase in the rate of DLB diagnosis, suggesting that a structured means of assessing symptoms and clinical features associated with DLB can assist clinicians in recognising cases. The assessment toolkit did not alter the overall rate of PDD diagnosis, suggesting that alternate means may be required to improve the rate of diagnosis of dementia in Parkinson's disease.

Indexed as

Lewy Body DiseaseParkinson DiseaseAgedHumansMemoryDementia with Lewy bodiesDiagnosisParkinson’s disease dementia

Identifiers

PMID33608039
PMCPMC7896389
OpenAlexW3128470224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.